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In vitro studies have demonstrated that cancer-speciﬁc T cell cytotoxicity can be induced both ex vivo and in vivo, but this
therapeutic strategy should probably be used as an integrated part of a cancer treatment regimen. Initial chemotherapy should
be administered to reduce the cancer cell burden and disease-induced immune defects. This could be followed by autologous
stem cell transplantation that is a safe procedure including both high-dose disease-directed chemotherapy and the possibility
for ex vivo enrichment of the immunocompetent graft cells. The most intensive conventional chemotherapy and stem cell
transplantation are used especially in the treatment of aggressive hematologic malignancies; both strategies induce T cell defects
that may last for several months but cancer-speciﬁc T cell reactivity is maintained after both procedures. Enhancement of
anticancer T cell cytotoxicity is possible but posttransplant vaccination therapy should probably be combined with optimalisation
of immunoregulatory networks. Such combinatory regimens should be suitable for patients with aggressive hematological
malignancies and probably also for other cancer patients.
1.Introduction
During the last two decades, eﬀects of immunotherapy and
autologous stem cell transplantation have been extensively
studied in the treatment of human cancer. Immunotherapy
often includes cancer vaccines, but vaccine-induced anti-
cancer reactivity is often not associated with signiﬁcant
clinical responses [1–3]. Similarly, high-dose chemotherapy
combined with autotransplantation has become a part of
routineclinicalpracticeonlyforaminorityofcancerpatients
due to limited clinical beneﬁts [4, 5].
Anticancer immune reactivity is probably important in
autotransplantation, because early lymphoid reconstitution
is associated with prolonged progression- or disease-free
survivalinmanymalignancies[6,7].Thishasbeendescribed
in patients with B-cell malignancies, acute myeloid leukemia
(AML), and solid tumors, suggesting that early reconsti-
tution represents a general anticancer eﬀect [7–10]. Even
though cancer patients often have both disease-associated
and treatment-induced immune defects that may persist for
several months [11], the combined use of autotransplanta-
tion and anticancer vaccines should be considered to try to
increase anticancer eﬀects.
In the present paper we review the experience with
intensive chemotherapy and immunotherapy for patients
receiving intensive chemotherapy for aggressive hemato-
logical malignancies. We focus on acute myeloid leukemia
(AML), one of the most aggressive human malignancies
that is usually treated with very intensive therapy even-
tually in combination with stem cell transplantation. The
experience from these patients is that anticancer immune
reactivity is maintained and can be induced after the
intensive treatment. It seems likely that similar therapeutic
strategies should be possible also in other patients receiving
less intensive chemotherapy for less aggressive malignan-
cies.2 Journal of Biomedicine and Biotechnology
2. Effects of Conventional Intensive
Chemotherapy on T Cells
2.1. Early Eﬀects of Chemotherapy on the T Cell System.
Patients with acute myeloid leukemia receive intensive
chemotherapy followed by a period of severe leukopenia, but
even these patients have a functional T cell system, and rapid
lymphoidreconstitutionisassociatedwithadecreasedriskof
AML relapse [11, 12]. T cell functions during cytopenia are
characterised by the following.
(i) Circulating T cells are mainly T cell receptor
(TCR)αβ+ with only a minority of TCRγδ+ cells. The
CD4/CD8 ratio varies considerably between patients
[13].
(ii) Chemotherapy-induced lymphopenia is not a ran-
dom process and these patients have a decreased
percentage of circulating clonogenic T cells. Their
most important growth factors are IL-2 and IL-15,
but several other cytokines can also cause detectable
T cell proliferation [14]. T cell proliferation can be
induced through the TCR-CD3 complex even in the
presence of AML accessory cells [14], and responses
are increased by CD28 mediated costimulation [15].
(iii) Activated T cells release several cytokines; high
levels are detected for IFNγ, IL-6 and GM-CSF and
detectable release of IL-2, IL-3, IL-4, IL-10, IL-13,
and TNFα is often seen [16]. These responses can
be enhanced by the protein kinase C agonist PEP005
[16].
(iv) Local T cell recruitment to the cancer cell compart-
ment is essential for antileukemic T cell reactivity,
and the chemotactic gradients are then determined
by the systemic serum levels and the local levels in
thecancercellcompartment.Thesystemiclevelsvary
between patients and can be inﬂuenced by several
factors, including the type of chemotherapy, patient
age, and complicating febrile neutropenia [17]. Con-
stitutive release of T cell chemotactic chemokines by
the cancer cells may be an important determinant of
the tissue chemokine levels [18].
Altogether, these observations clearly demonstrate that a
functional T cell system remains during the severe post-
treatment leukopenia even for patients receiving the most
intensive conventional chemotherapy, and T cell targeting
therapy may be possible even during this period.
2.2.LateEﬀectsofChemotherapyonCirculatingTCells. Stud-
iesofimmunologicalreconstitutionafterconventionalinten-
sive chemotherapy has been carried out for patients with
nonHodgkin’s lymphoma, sarcomas and brain tumors, but
these patients generally received less intensive chemother-
apy than patients with AML [19–23]. These studies have
described a decrease in circulating CD4+ cells that may
last for several months, and there seems to be a pre-
dominance of memory-type (CD4+CD45RO+CD45RA+/−)
cells. This defect seems to be at least partly age-dependent
a n di sl e s sp r o n o u n c e di nc h i l d r e n[ 23]. The number of
CD3−CD16+CD56+ NK lymphocytes is usually normalised
within 6 weeks [24]. It seems likely that similar defects
are also seen after conventional chemotherapy for other
malignancies, including the most intensive AML therapy.
Certain drugs seem to cause more severe CD4+ T cell defects;
thisisespeciallytrueforﬂudarabinethatcanbeusedasapart
of conventional chemotherapy and in the reduced intensity
conditioningbeforeallogeneicstemcelltransplantation[25].
Finally,theeﬀectofchemotherapyonTregcellsseemtodiﬀer
between cytotoxic drugs as reviewed recently [26], myeloid
suppressor cells can be transiently increased early after
recovery from chemotherapy and the heterogeneity within
thedendriticcellpopulationvariesduringtherecoveryphase
after chemotherapy [27]. The status of all these three cell
types may inﬂuence the response to anticancer vaccines.
3.ImmunocompetentCellsin
Autologous Stem Cell Grafts
3.1. Sources of Hematopoietic Stem Cells: Bone Marrow
versus Peripheral Blood Harvesting. Hematopoietic stem cells
(HSC) are now preferably harvested from peripheral blood
after growth factor mobilisation [28, 29], and this method is
associated with earlier engraftment than HSC aspired from
bone marrow [30]. Neutrophil engraftment with peripheral
blood neutrophils >0.1 × 109/L is usually seen within 10–
12 days and platelet engraftment with thrombocytes >20
× 109/L within 12–14 days [30, 31]. The conclusion from
the overall results is therefore very clear: (i) mobilisation of
peripheral blood stem cells is safe and eﬀective; and (ii) the
short time until hematopoietic reconstitution when using
mobilised cellshasincreasedthesafetyoftheprocedure[32].
3.2. Preparation of Peripheral Blood Stem Cell Grafts. G-CSF
is the most widely used drug for stem cell mobilisation
[33] and is thought to stimulate immature stem cells to
p r o d u c ep r o g e n i t o r so fa l lc l a s s e s[ 34]. In addition G-CSF
indirectly stimulates the production of progenitor cells by
increasing the production of hematopoietic growth factors
[35] and it promotes the release of progenitors into the
general circulation [35]. When administered early after
chemotherapy, G-CSF acts synergistically with the natural
increase in HSC that is seen during the recovery phase
[36]. The morbidity during and after G-CSF mobilisation is
very low [37], and the most frequent side eﬀects are bone
pain, fever, and nausea. Successful mobilisation can also be
achieved with longer-acting G-CSF (pegylated G-CSF) [38]
its main advantage is less frequent administration [33].
Several strategies have been tried to increase the mobil-
isation of CD34+ cells. A combination of G-CSF plus stem
cell factor (SCF) will often more than double the yield of
CD34+ cells compared to G-CSF alone [39, 40]. The CXCR4
antagonist AMD3100 can also be combined with G-CSF to
improve HSC mobilisation [41–43]. Finally, even though
mobilisationregimensthatincludechemotherapyhavemore
side eﬀects than G-CSF alone [37], the use of chemotherapy
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is more common in cancer patients with G-CSF alone [44],
and the disease-speciﬁc chemotherapy in such regimens can
have additional anticancer eﬀects.
3.3. Cryopreservation of Peripheral Blood Stem Cell Grafts:
Eﬀects on Immunocompetent Cells. Autologous stem cell
grafts are usually cryopreserved, and the protocols are
generally based on the use of the cryoprotectant dimethyl
sulphoxide (DMSO) in the freezing medium [45–47]. After
harvesting, the ﬁnal product is often diluted with autologous
plasma if the nucleated cell concentration is higher than 200
× 106 cells/mL to improve cell viability [48]. Most centers
will use a controlled programmed freezer and storage in
nitrogen at −160◦C.
The grafts are usually prepared by apheresis procedures
alone without further enrichment of CD34+ stem cells,
and large numbers of immunocompetent cells are therefore
reinfused together with the stem cells. Early posttransplant
lymphocyte reconstitution after both auto- and allotrans-
plantation is associated with prolonged relapse-free survival
in several malignancies [7–10]. For allotransplanted patients
reconstitution of CD4+ T cells seems particularly important,
andinfusionofahighnumberofCD4+ TcellsandNKTcells
seems to be associated with a better prognosis [49]. This may
also be true for autografted patients, and these observations
suggest that immunological events early after reinfusion
are important for the risk of later relapse/progression. The
amount and quality of reinfused lymphocytes may therefore
be essential.
We investigated the viability of total lymphocytes and
the distribution of various T cell subsets in peripheral
blood stem cell autografts after long-term storage with
2%, 4%, 5% and 10% DMSO [50]. The viability of the
total lymphocyte population was signiﬁcantly higher for
cells preserved in 4% and 5% DMSO, but the DMSO
eﬀect diﬀered between T cell subsets (Table 1). First, NKT
cell viability was dependent on the DMSO concentration
used. Second, naive and central memory T cells usually
express CD62L, late eﬀector T cells show intermediate/low
expression, while eﬀector memory T cells do not express
CD62L [51]. The eﬀect of DMSO diﬀered between these
CD62L-deﬁned T cell subsets. Third, the CCR7 chemokine
receptor is expressed by naive and central memory T
cells and directs migration to lymph nodes; this homing
process is important for initiation of immune responses
[52]. Again the DMSO eﬀect diﬀered between CCR7-
deﬁned subsets and also between CCR2/CCR4 deﬁned
subsets. Finally, Foxp3 positive T cells are referred to as
thymus-derived natural T regulatory (Treg) cells [53]. The
percentage of CD4+CD25+Foxp3+ cells among CD4+ Tc e l l s
was signiﬁcantly lower after cryopreservation with 10%
DMSO.
Several NK cell subsets have now been characterised,
including immunoregulatory (CD3−CD56brightCD16low/neg)
and cytotoxic cells (CD3−CD56dimCD16bright)[ 54–56]. Cry-
opreservation with various DMSO concentrations did not
alter the percentages among viable graft lymphocytes of total
NK cells (CD3−CD56+) or the various NK cell subsets [50].
Taken together these results suggest that the procedures
used for cryopreservation aﬀect lymphocyte viability; this
is not a nonspeciﬁc eﬀect but rather an eﬀect that diﬀers
between various T cell subsets and it may thereby aﬀect post-
transplant T cell reconstitution and immunocompetence.
The mobilisation and harvesting procedures would also be
expected to inﬂuence the graft lymphocyte content but to
the best of our knowledge this has not been investigated in
clinical studies.
3.4. Enhancement of Antileukemic Reactivity in Autologous
Stem Cell Grafts. The studies described above demonstrate
that cytotoxic T cells are preserved and reinfused in autol-
ogous stem cell grafts. Furthermore, recent studies have
demonstrated that T cells speciﬁc for leukemia-associated
antigens remain in the circulation after intensive AML
chemotherapy (see Section 5), and for this reason one would
expect such cells also to be present in the autografts. At
present it is not known whether reinfusion of such cells as
a part of the transplantation procedure will have any clinical
impact, or whether the immunocompetent cells in the graft
will diﬀer between various mobilisation procedures.
It is possible to separate graft cells into CD34+ and
CD34− c e l l sb e f o r ef r e e z i n g[ 57], and the CD34− subset
could then be used for ex vivo enrichment of cancer-
reactive T cells before reinfusion together with the CD34+
cells. Although techniques for enrichment of leukemia-
reactive T cells are available, they have not been used in
a large-scale clinical setting in combination with stem cell
transplantation.
3.5. The Possible Use of Ex Vivo Expanded Cancer-Reactive
TC e l l s .As stated above, in vitro expanded autologous T
cells can be used in the treatment of cancer. This strategy
has not been widely used in the aggressive hematological
malignancies, but the experiences from solid tumors (e.g.,
malignant melanoma) suggest that such cells can induce
clinically relevant antitumor activity [27, 58]. In a recent
study a comparable strategy was also used as a posttrans-
plant treatment in allotransplanted patient; donor-derived
leukemia-reactive T cells were then reinfused in patients
with leukemia relapse after allotransplantation [59]. Taken
together these studies suggest that infusion of ex vivo
generated cancer-reactive T cells can be combined with




T cell functions during the early posttransplant period
with severe treatment-induced leukopenia seem to be very
similar to AML patients receiving intensive conventional
chemotherapy, and the later reconstitution also shows many
similarities[60](Table 2).T imeuntilc ompleteimmunologi-
cal reconstitution in adults may take years [61–63]. However,
after transplantation the absolute number of circulating
CD3+ cellsusuallyremainsdecreasedforthreetoﬁvemonths4 Journal of Biomedicine and Biotechnology
Table 1:Cryopreservationofautologousperipheralbloodstemcellgraftsincancerpatients;asummaryoftheeﬀectsonimmunocompetent
cells when grafts were prepared with 2%, 4%, 5%, and 10% DMSO.
T cell population Functional characteristics Eﬀects of cryopreservation with DMSO at various concentrations
Major T cell subsets
CD3+CD4+ Th e l p e r N oe ﬀect of diﬀerent DMSO levels
CD3+CD8+ Cytotoxic No eﬀect of diﬀerent DMSO levels
CD3+CD56+CD16+ NK T cells Highest viability with 2% DMSO
CD3+CD56+CD16− NK T cells Highest viability with 2% DMSO
CD62L-deﬁned subsets
CD4+CD62+,C D 8 +CD62+ Naive and central memory Highest viability when using DMSO 5%
CD4+CD62low,C D 8 +CD62low Late eﬀector T cells CD4+ cells show highest viability with DMSO 2% and 4%
CD4+CD62−,C D 8 +CD62− Eﬀector memory No eﬀect of diﬀerent DMSO levels
Subsets deﬁned by chemokine
receptor expression
CD4+CCR7+,C D 8 +CCR7+ Naive and central memory T cells The CD4+ cells showed decreased viability when using 10% DMSO
CD3+CD45+CCR4−CCR6− Decreased viability when using 2% DMSO
Other CCR2, CCR4, CCR7 No eﬀect of diﬀerent DMSO levels
deﬁned T cell subsets
CD4+CD25+FoxP3+ Tc e l l s Natural regulatory T cells Decreased viability when using 10% DMSO
Autografts were prepared for cancer patients after mobilisation with chemotherapy plus G-CSF. After the aphereses cell concentrations were adjusted and cells
stored in nitrogen for 5-6 years as described in the text [50].
[64]. Low levels of circulating CD4+ cells have been reported
for 12–18 months [65], whereas CD8+ T cells usually
recover within 3–12 months [64]. Defective proliferation
of both CD4+ and CD8+ T cells in response to antiCD3
and antiCD2 persists for at least for 2–4 months, and this
seems to be caused by defective IL-2 responsiveness [64, 66].
Furthermore, the speciﬁc cytotoxic T cell response against
Epstein-Barr virus is signiﬁcantly impaired for 2–5 months
[67], whereas the frequency of circulating cytokine-secreting
T helper cells and IL-2 responding T cells can be decreased
f o ru pt o5y e a r sp o s t t r a n s p l a n t[ 68].
Peripheral blood mobilized stem cells (PBMSC) are
now used for most cancer patients treated with autologous
stem cell transplantation. The immunological reconstitution
diﬀers between patients receiving peripheral blood and bone
marrow autografts [64], and the following data on T cell
subset reconstitution refers to patients transplanted with
mobilized stem cells. PBMSC autografted patients show
early recovery of CD14+ monocytes and CD56+ NK cells
during the ﬁrst month after autotransplantation [64, 69,
70]. The homeostasis of total circulating dendritic cells
is usually achieved relatively early after transplantation,
although diﬀerences in dendritic cell subset composition
may be detected for several months [70]. However, as
pointed out by these authors the kinetics of dendritic cell
reconstitution may diﬀer between patients and also depend
on the chemotherapy regimen [70] .I nc o n t r a s t ,al o n g -
lasting T cell defect similar to chemotherapy-treated patients
is also observed after autotransplantation [69, 70]. This
defect is detected after 6 months for most patients, and for
a minority the defect will last for more than a year [69].
Table 2: T cell reconstitution after autologous stem cell transplan-
tation.
Immunocompetent cell Time until reconstitution
Number of circulating CD4+ T cells 1–5 years
Number of circulating CD8+ T cells 3–12 months
T cell proliferation 3 months–5 years
T cell cytokine production 6 months–5 years
T cell response to exogenous IL2 7 months–5 years
Cytotoxic T cells 2 months–5 years
Adapted from article by Porrata et al. [60]. In general there is considerable
variability in the data that have been found for T cell reconstitution, both
in-between patients and studies. Thus, the timeframes indicate when the
majority of patients can expect to reach normal values.
The total levels of CD8+ T cells seem to normalize within
a few months, whereas total CD4+ Tc e l lc o u n t sr e m a i n
decreased for several months. The CD4 defect is mainly due
to a reduction of naive CD3+CD4+CD45RA+ T cells, and
there seems to be a reduction even of CD8+ naive T cells
[69, 70].
As discussed by Dreger age may inﬂuence the T
cell reconstitution after autotransplantation [69]. Immuno-
genetic factors may also be important for posttrans-
plant T cell functions; single nucleotide polimorphisms
in immunoregulatory chemokine/cytokine genes seem to
inﬂuence the risk of infections, graft versus host disease and
leukemia relapse after allogeneic stem cell transplantation.
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Loeﬄer [71]). Such immunogenetic inﬂuences may also be
important for the response to posttransplant vaccination
therapy after conventional chemotherapy or stem cell trans-
plantation.
The number of mature B cells is markedly decreased
during the ﬁrst 3 months posttransplant, but will thereafter
gradually increase although complete normalisation may
take up to 18 months [64]. Both T cell-dependent and
independent B cell response are decreased for 12–18 months
[72], and the IgM production will normalise earlier (often
within 6 months) than the corresponding IgG response [72].
NK cells usually recover within 1 month after transplan-
tation [73]. The NK cell number is often increased on day
15 posttransplant compared with normal individuals, but
by day 75NK cell activity has usually returned to a normal
level. NK cells are important for rejection of malignant
cells [74], and pharmacological agents that increase cancer
cell susceptibility to NK cell mediated lysis are now being
developed [75].
As described in a recent review the immunological
reconstitutionafterallogeneicstemcelltransplantationdiﬀer
between patients receiving myeloablative and reduced inten-
sity conditioning therapy [25]. Brieﬂy, allotransplantation is
also associated with a similar quantitative defect in CD4+ T
cells, this defect may last for several months but early nor-
malization seems to be more common for patients receiving
reduced intensity conditioning (for detailed discussion and
additional references see [25].
5. Inductionof Anticancer Reactivityby
VaccinationIs Possible inHeavily
Pre-Treated Patients
A major question is whether it is possible to induce
anticancer T cell reactivity and especially cytotoxicity in
patients who have recently received intensive chemother-
apy. T cells speciﬁc for cancer-associated antigens can be
detected in healthy individuals and also in untreated cancer
patients despite their disease-induced immunosuppression,
and many of these cells seem to be CD8+ cytotoxic eﬀector
memory cells [76]. Many cancer patients develop additional
therapy-induced immune defects. However, if it is possible
to induce anticancer T cell reactivity by vaccination in
AML patients who have a very aggressive disease and
receive the most intensive chemotherapy, one would expect
immunotherapy to be eﬀective also in other cancer patients.
Several strategies for immunotherapy in AML have been
tried (Table 3). In this paper we will review the results from
vaccination studies.
5.1. AML-Associated Peptide Antigens Used for Vaccination.
AML patients are very heterogeneous with regard to genetic
abnormalities encoding leukemia-speciﬁc antigens [77]. To
ﬁnd a common vaccination strategy the available studies
have therefore focused on the use of either whole AML cells
(cell lysates or modulated AML cells) or peptides derived
from AML-associated proteins.
WT1 is a zinc ﬁnger transcription factor that is expressed
in normal CD34+ hematopoietic cells, myoepithelal progen-
itors, renal podocytes, and some cells in testis and ovary
[78]. This protein is overexpressed in several hematological
malignancies and solid tumors [78]. Antibodies against
this molecule have been detected in cancer patients and
several immunogenic peptides have been identiﬁed [78].
Brieﬂy, both CD4 and CD8 T cell epitopes have been
identiﬁed, and HLA-A0201 and HLA-A24-restricted CD8+
T cell cytotoxicity against WT1 expressing cancer cells have
been detected. The CD4 peptides bind to diﬀerent HLA-
c l a s sI Im o l e c u l e sa n di n d u c eC D 4 + T cell responses that
enhance cytotoxic T cell reactivity either through induction
of CD4+ cytotoxic T cells or through induction of CD4+
Th1 helper cells. Some peptides include epitopes recognised
both by CD4+ and CD8+ T cells. Finally, a recent study
demonstrated that WT1-speciﬁc cytotoxic T cells remain
even after remission-inducing intensive AML chemotherapy
[79].
Proteinase 3 is a diﬀerentiation antigen that is also
overexpressed in leukemic blasts [78]. A proteinase 3-
derived peptide named PR1 has been identiﬁed by screening
for binding avidity to HLA-A0201 [78]. In vitro studies
suggest that PR1-speciﬁc T cells can kill leukemic cells,
including the more immature clonogenic subsets, but not
normal hematopoietic stem cells [78, 80, 81]. However, it
should be emphasized that these data are mainly based on
studies of healthy individuals and cancer patients receiving
low-toxicity chemotherapy. Untreated AML patients have
also been investigated and circulating PR1 speciﬁc T cells
could not be detected then [78]. This may be due to
apoptosis of high-avidity T cells induced by exposure to
high peptide concentrations or leukemic cells overexpressing
the proteinase 3 [78]. However, PR1 speciﬁc T cells can be
detected later after remission-inducing AML chemotherapy
[79].
The receptor for hyaluronic-acid-mediated motility
(RHAMM) is overexpressed in leukemic blasts from AML
and CML patients but not in normal CD34+ hematopoietic
cells [78]. Greiner et al. identiﬁed a RHAMM-derived
peptide (referred to as the RHAMM-R3 peptide) that could
bepresentedbyHLA-A2andrecognisedbyCD8+ Tcells[78,
83]. This peptide was a naturally processed T cell epitope,
speciﬁc T cells were detected in AML patients even following
intensive chemotherapy, and in vitro primed T cells could
lyse human AML blasts.
Taken together these studies clearly demonstrate that
cancer-speciﬁc, HLA-restricted T cell reactivity, including
speciﬁc cytotoxicity, is maintained even after the most
intensive chemotherapy.
5.2. Peptide Vaccination in AML. Oka et al. investigated the
eﬀect of WT1 peptide vaccination in 26 cancer patients,
including 13 patients with de novo AML [84]. They used
intradermal injection of a modiﬁed 9-mer WT1 peptide
emulsiﬁed in Montanide ISA51 adjuvant; 18 of the 26
patients completed the vaccination protocol with 3 or
more injections every second week and most patients were6 Journal of Biomedicine and Biotechnology
Table 3: Immunotherapy in AML; the advantages and disadvantages of the various approaches that have been investigated in clinical trials
[82].
Strategy Advantage Disadvantage
Peptide vaccination Easy to produce and administer
Selection of patients with certain HLA
types and high antigen expression in the
malignant cells
Normal dendritic cells loaded
with AML-associated peptides
Presentation of several leukemia-speciﬁc
and leukemia-associated antigens
Work-consuming in vitro procedures for
preparation and antigenic loading
(lysates, mRNA).
Whole tumor cell vaccines with
irradiated AML cells:
(i) Leukemic cells plus
systemic administration of Relatively easy to prepare, several
antigens presented Clinical side eﬀects immunostimulatory
cytokines
(ii) Modiﬁed leukemic cells Several antigens presented Complicated and work-consuming ex
vivo handling expressing GM-CSF or
CD80+IL2
Leukemic dendritic cells Presentation of several leukemia-speciﬁc
and leukemia-associated antigens
Heterogeneity between patients with
regard to eﬃciency; work-consuming in
vitro procedures for preparation and
antigenic loading (lysates, mRNA).
IL-2 therapy Easy to administer, induces innate and
speciﬁc immunity Serious side eﬀects
vaccinated with a modiﬁed peptide that gave stronger
cytotoxic T cell responses than the natural peptide. All
patients were HLA-A2402 positive and their malignant cells
showed high WT1 expression. Tetramer ﬂow cytometry of
circulating cells showed an increase in speciﬁc T cells during
vaccination for 9 of the 13 AML patients. An increase
in antigen-speciﬁc induction of IFNγ expression was also
observed for 6 of the patients. Only 10 of these patients
could be evaluated with regard to clinical responses: (i) 2
patients showed decreased residual AML; (ii) stable disease
was seen for 2 patients; (iii) bone marrow expression of
WT1 was used as a surrogate marker of residual disease for
those patients without detectable AML blasts, and for 5 of
these patients decreased expression was detected following
vaccination; (iv) 1 patient showed progressive disease. There
was a statically signiﬁcant correlation between clinical and
immunological responsiveness. These observations suggest
that WT1 vaccination can induce a speciﬁc T cell response;
these T cells can locate to the bone marrow compartment
and they mediate WT1-speciﬁc antileukemic eﬀects.
Another study examined a regimen with GM-CSF ther-
apy on days 1–4 and vaccination with antigenic peptide +
keyhole limpet hemocyanine on day 3 [1]. All patients were
HLA-A2 positive and had high expression of WT1 in their
leukemiacells,17outofthe19includedpatientshadreceived
previous chemotherapy and all patients had detectable AML
with increased bone marrow blasts. The vaccines induced
immunological responses judged from tetramer analyses of
peripheral blood, and a signiﬁcant increase of these cells was
also seen in the bone marrow. Importantly, responses were
recorded especially in patients that had received previous
chemotherapy and showed relatively low levels of bone
marrow blasts (<5 0 % ) .R e d u c t i o no fb o n em a r r o wW T 1
levels was observed for a subset of patients following
vaccination. Thus, previous intensive chemotherapy does
not eradicate leukemia-reactive T cells; the chemotherapy-
induced reduction of the AML cell burden rather seems to
reducedisease-inducedimmune defectsandtherebyincrease
the eﬃciency of the vaccination.
PR1 responses have been investigated in a study that
combined vaccination with WT1 and PR1 peptides [81].
This vaccine was also based on concomitant GM-CSF
administration and subcutaneous administration of pep-
tides in Montanide adjuvant. Five AML patients in com-
plete remission after previous intensive chemotherapy were
included. Responses were evaluated by tetramer staining,
and immunological responses were detected for one or both
peptides in most patients. Increased T cell responses were
also detected by IFNγ expression after speciﬁc stimulation.
Bone marrow expression of WT1 was used as a surrogate
marker for residual disease, and these levels decreased when
immunological responses became detectable. Thus, even
though in vitro exposure of PR1-speciﬁc T cells to AML
cells with high antigen levels causes apoptosis of these cells
(see Section 5.1), detectable PR1 T cell responses could be
induced early after induction chemotherapy.
The RHAMM-R3 peptide identiﬁed in previous in vitro
studies has been tried for vaccination in HLA-A2+ patients
with hematological malignancies [85]. This study included
only 10 patients with AML, MDS, or multiple myeloma;
all 3 AML patients had received intensive chemotherapy
before vaccination and the 4 myeloma patients had received
autologous stem cell transplantation. The vaccine consisted
of injection of 300μg peptide in incomplete Freund adjuvantJournal of Biomedicine and Biotechnology 7
subcutaneously on day 3, GM-CSF was administered on
days 1 and 5, and this cycle was repeated 4 times with 2-
weeks intervals. Immunological responses were evaluated
by tetramer ﬂowcytometry and ELISpot analysis for IFNγ
and Granzyme B. An immunological response was detected
by at least one of these methods for 9 patients, only
1 AML patient in relapse did not respond. Vaccination-
induced T cell cytotoxicity towards autologous AML cells
or HLA-A2+RHAMM+ target cells could also be detected.
A clinical response with further reduction of bone marrow
blasts was observed for 1 AML and 2 MDS patients. This
study illustrates that T cell reactivity against leukemia-
associated antigenic epitopes is maintained after intensive
conventional chemotherapy as well as autologous stem cell
transplantation, and this reactivity can be enhanced by
peptide vaccination.
The clinical toxicity of vaccination was generally low,
the most common side eﬀect being grade 1-2 reactions with
pain and erythema at the injection site. One study observed
progressing leukopenia in two patients with MDS and MDS-
AML, respectively; this may be caused by immunological
reactivity against normal stem cells in patients with disease-
induced reduction of normal hematopoiesis [3]. Oka et al.
alsodescribedapatientwithafebrilereactionduringtheﬁrst
injection [3].
5.3. Cell Vaccines. A recent article described two patients
vaccinated with ex vivo generated monocytic dendritic cells
that had been incubated with leukemic cell lysates and
keyhole limpet hemocyanine [86]. Subcutaneous injection
of the pulsed dendritic cells was well tolerated. Another
study also investigated preparation of monocyte-derived
dendritic cells in AML; these authors combined ex vivo
generation of the cells followed by cryopreservation before
transfection of WT1 mRNA by electroporation [87]. The
procedure was successful for all patients and injections were
well tolerated. It is diﬃcult to see from these articles whether
immunological responses were induced by the vaccination.
An additional advantage with this approach could also
be activation of NK cells and not only speciﬁc T cells
and thereby induction of an additional anticancer eﬀect
[88].
PrimaryhumanAMLcellscanbeinducedtodiﬀerentiate
in the direction of a dendritic cell phenotype by exposure
to various cytokines or cytokine combinations. These cells
show dendritic morphology, increased expression of T cell
costimulatorymolecule,increasedantigen-presentingcapac-
ity and a constitutive chemokine release proﬁle consistent
with a dendritic cell phenotype [89, 90]. One study has
reported the eﬃciency and toxicity when using a vaccine
basedonsubcutaneousinjection ofdendritic AMLcells[91].
Five patients treated in a palliative setting were included, and
the authors observed increased immune responses towards
a peptide derived from the leukemia-associated antigen
PRAME. Thus, this methodological approach also seems to
beeﬀectiveand feasible.However, careshouldbe takenwhen
injecting ex vivo expanded cells, and possibly the cells should
be irradiated before injection [89].
Even though the experience with dendritic cell vaccines
in aggressive hematological malignancies is limited, the
experience from other malignancies is promising [92]. The
dendritic cells orchestrate a repertoire of immune responses,
butvariousdendriticcellsubsetsdiﬀerintheirimmunoregu-
latorycharacteristics[93].Dendriticcellvaccinescanthereby
be used for cross-presentation of cancer-associated antigens;
a possible approach then being to load the cells with
autologous cancer cell lysates [94]. This therapeutic strategy
seems safe and eﬀective. As an example, a recent study in
patients with lung cell cancer showed no serious side eﬀects
and increased T cell responsiveness to cancer-associated
antigens for more than half of the patients vaccinated
with antigen-loaded autologous dendritic cells [94]. Another
strategy is viral transfection of cancer-associated antigens
alone or antigens together with various immunostimulatory
molecules [95, 96]. The experiences from other cancers
suggest that such therapeutic strategies should be further
investigated also in hematological malignancies, and com-
bination of chemotherapy and dendritic cell vaccination
should then be possible. However, the optimal procedures
for antigenic loading and dendritic cell preparation remain
to be established.
6. FutureDirections
6.1. Design of the Chemotherapy in Combination Regimen.
The general intensity of the chemotherapy has to be decided
based on a clinical evaluation of the patients, and one
has to take into consideration that there is evidence from
clinical studies that a low cancer cell burden is associated
with increased anticancer T cell reactivity [1, 97]. Several
additional points also have to be considered. Firstly, if
possible one should use a regimen that induces immuno-
genic cancer cell apoptosis that will enhance anticancer
immune reactivity; this has been described especially for
the anthracyclines [98]( Figure 1). Second, if possible the
chemotherapy should reduce the levels of regulatory T cells
[99] (see Section 6.3). Finally, the vaccine studies described
above started at least 4 weeks after chemotherapy, but
even patients with severe chemotherapy-induced cytope-
nia have an operative T cell system and immunother-
apy can probably start even earlier after chemotherapy
[100].
6.2. The Advantage of Including Autologous Stem Cell
Transplantation. There are several possible advantages if
autotransplantation is combined with vaccination therapy.
Firstly, additional disease-directed chemotherapy can be
administered both for mobilisation and as high-dose inten-
sive chemotherapy before transplantation; this is safe and
may further reduce the cancer cell burden [101]. Sec-
ondly, graft preparation oﬀers the possibility to manipulate
the immunocompetent graft cells and thereby combine
chemotherapy and immunotherapy. CD34 enrichment is
now possible as a part of routine therapy before cry-
opreservation [102], and by using similar methodological






Figure 1: Induction of immunogenic apoptosis. Certain chemo-
therapeutics agents (e.g., the anthracyclines) will induce immuno-
genic apoptosis in cancer cell through induction of Danger-
Associated Molecular Patterns (DAMPs). Examples of DAMPs are
various Heat shock proteins and ecto-calreticulin exposure on the
cancer cell surface. This pattern will induce dendritic cell (DC)
maturationwithdevelopmentofspeciﬁcThelpercellresponsesand
enhancement of cancer-speciﬁc T cell cytotoxicity.
could enrich anticancer cytotoxic T cells and reinfuse them
as a part of the transplantation procedure. Finally, even
though both chemotherapy and autotransplantation seem to
induce a general quantitative CD4+ T cell defect, intensive
chemotherapy does not eradicate cancer-speciﬁc T cells and
enhancement of this reactivity in graft immunocompetent
cells or posttransplant cells should therefore be possible.
6.3. The Vaccination Procedure. The administration route of
vaccines will probably be important. For example, animal
experiments have shown that dendritic cells administered
subcutaneously will localise to the draining lymph nodes,
whereas intravenous administration will cause localisation
to the spleen [103]. Several techniques are now available
for preparation of the vaccines; these strategies have been
reviewed recently and are exempliﬁed by the results summa-
rized in Figure 2 and Tables 3 and 4 [82, 104].
Manipulation of immunocompetent cells through stim-
ulation of Toll-like receptors (TLR) seems to be of particular
interest [108, 109]. TLR9 is expressed by dendritic cells and
B cells, and CpG oligonucleotides can be used as TLR9
agonists. These oligonucleotides will increase anticancer
immune reactivity through several mechanisms, including
increased presentation of cancer-associated antigens by den-
dritic cells [105–107, 110]( Figure 2) .T h e s ea g e n t sh a v eb e e n
used alone, but they can also be used as adjuvants in cancer
vaccinesandbecombinedwiththeMontanideadjuvantused
inthepeptidevaccines(seeSection 5.2).However,theoverall
results from experimental and clinical studies with regard to
eﬀects of adjuvants on T regulator cells (Treg) are conﬂicting
and require further studies.
Other adjuvants should also be tried in vaccination
therapy, especially chemokines that are now considered as
possible therapeutic targets in proinﬂammatory conditions
[111]. These mediators can be released by malignant cells
and have several biological eﬀects including chemotactic,
growth-stimulatory, immunomodulatory, and angioregula-
tory eﬀects [26, 43, 112]. Other cytokines than GM-CSF
are now investigated as vaccine adjuvants, including Flts-
ligand as well as the chemokine CCL5 and CXCL9 [113–
115]. These experiences from animal cancer models suggest
that such approaches should be tried also in the treatment
of human cancers, although the possible roles of chemokine
decoy receptors have to be explored [116].
An alternative to in vivo expansion of antigen-speciﬁc
T cells through vaccination would be ex vivo enrichment
of speciﬁc cells followed by infusion of these cells. Based
on experimental observations various strategies may be
possible, including (i) stimulation and thereby in vitro
prokiferation/expansion of antigen-speciﬁc T cells; or (ii) ex
vivo generation of antigen-speciﬁc T cell reactivity through
viral transduction of speciﬁc T cell receptor genes. First,
antigen-loaded dendritic cells can be used to stimulate
proliferation of cancer-speciﬁc cells, and this expansion can
be increased by subsequent costimulation through CD28
[117, 118]. Costimulation through the CD40/CD40-ligand
system may also be possible [119]. Second, T cell receptor
gene-modiﬁed lymphocytes can be generated, such cells
persist in patients after infusion and reduction of tumor
cell burden has been described [120, 121]. Whether in vivo
(vaccination) and ex vivo expansion (in vitro culture) of
cancer-reactive T cells can be combined in cancer patients
has not been clariﬁed, and future studies also have to
clarify whether these therapeutic strategies will be eﬀective
in hematologic malignancies.
6.4. Targeting of Immunoregulatory Cells Together with
Leukemia-Speciﬁc Cytotoxicity: The Importance of Th17 Cells
and Treg Cells. IL-17 is a family of T cell derived cytokines
that triggers the production of proinﬂammatory cytokines
and chemokines by a wide range of cells, including epithelial
cells, endothelial cells and macrophages [122, 123]. In
healthy individuals circulating Th17 cells constitute less
than 1.0–1.5% of total circulating T cells [124], increased
levels are observed in patients with advanced cancers, and
tumor inﬁltrating Th17 cells have been detected in ovarian,
pancreatic and renal cell cancer [125]. Several experimental
observations suggest that Th17 cells can increase speciﬁc
antitumor immune activity [126]a sw e l la sa n t i c a n c e rN K
cell reactivity [127]. These animal studies suggest that the
role of Th17 cells in human cancer should be further
investigated, including the cryopreservation of Th17 cells in
autologous stem cell grafts and the possibility to enhance
anticancer reactivity through ex vivo enrichment of Th17
cells in the autografts before reinfusion.
Immunosuppressive Treg cells comprise 5–15% of
peripheral CD4+ T cells [128, 129]. In animal models
these cells prevent autoimmune diseases, graft rejection and
anticancer reactivity [128, 130]. Several studies suggest that
cytotoxic agents can alter the levels of Treg cells. Fludarabine
therapy in patients with chronic lymphocytic leukemia often
causes a decrease or abrogation of the activity of Treg cells
[131]. Suppression of Treg cells by cyclophosphamide may
allow immunotherapy of established tumors to be curative
in animal models [132], but no eﬀect is observed after a sin-
gle cyclophosphamide infusion combined with nonspeciﬁcJournal of Biomedicine and Biotechnology 9
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Figure 2: The immunostimulatory eﬀect of TLR9 ligation by CpG oligonucleotides. (a) TLR9 is normally activated by nonmethylated
CpG dinucleotides (DNA motifs). In vaccination therapy TLR9 can be activated by synthetic oligodeoxynucleotides (ODN) containing
CpG motifs (CPG ODN), these molecules can be linked to antigenic peptides (Ag CpG ODN). This complex is endocytosed by dendritic
cells (DC); the antigen is then presented and CpG ODN enhances the accessory cell function of the dendritic cells [105–107]. (b) Binding
of CpG ODN by TLR9+ dendritic cells initiates signal transduction through members of the IL-1 receptor-associated kinase (IRAK)
family, mitogen activated kinases (MAPK) or Interferon (IFN) regulatory factors. These events lead to activation of nuclear factor kappa
B( N F κB) transcription factors with increased cytokine release and expression of costimulatory molecules [108]. (c) Inhibitory control
mechanisms of CpG-mediated immune activation seem to include induction of IL-10, cyclooxygenase-2 (COX-2), NO synthase 2 (NOS-2)
and prostaglandin E2 (PGE2). Intravenous administration of CpG ODN to mice induce splenic expression of the enzyme indoleamine 2,3-
dioxygenase (IDO) that is an enzyme associated generation of regulatory T cells (Treg) and thereby inhibition of Th1 cells, cytotoxic T cells
(Tc cells) and B cells [108].




Skin or muscle injection of cDNA encoding the antigen. Protein is endogenously produced, and
the epitopes can be combined with sequences from the carrier proteins or adjuvant proteins that
increase immunogenicity
Liposomal vaccines
Antigens are supposed to be delivered both for endosomal (CD4+ responses) and cytosolic
processing (CD8+ responses), combination with adjuvant is possible and custom-made vaccines
can rapidly be produced.
Increasing antigen presentation
Normal dendritic cell vaccines Dendritic cells are regarded as the most powerful antigen-presenting cells; the cells can be pulsed
by either cell lysates, heat shock proteins with bound client proteins or apoptotic cell organelles.
CpG vaccines
Dendritic cells are activated via toll-like receptors; these antigen-presenting cells will take up
cancer-derived peptides and this approach thereby bypasses the step of custom-made vaccines.
One approach is pre-vaccination local therapy that induces apoptosis, and local CpG-injection
will then enhance the uptake and presentation of peptides derived from malignant cells
Malignant dendritic cells Can be prepared for various hematological malignancies; these cells will present several
tumor-speciﬁc as well as tumor-associated antigens.10 Journal of Biomedicine and Biotechnology
immunotherapyinpatientswithmetastaticcarcinoma[133].
The mTOR antagonist rapamycin that is used in anticancer
therapy, increases the number of Treg cells [134], whereas
docetaxel does not seem to have any eﬀect [135]. Thus, the
eﬀects of anticancer therapy on Treg levels seem to diﬀer
between therapeutic agents.
Previous studies in AML have demonstrated that
increased Treg cells are detected in patients with newly
diagnosed AML, and these high levels persist even after
intensive chemotherapy and induction of disease control
with hematological remission [136]. Thus, the overall inten-
sity of the chemotherapy is not decisive for elimination of
these cells; rather the design and use of speciﬁc drugs seem
to be essential. Experimental studies have demonstrated that
suppressive Treg cells can be stimulated to develop into
proinﬂammatory Th17 cells [137]. The possibility to use
this approach instead of chemotherapy for elimination of
Treg cells and enhancement of immunoreactivity should be
explored both with regard to ex vivo manipulation of stem
cell grafts and in vivo immunomodulation.
6.5. The Roles of Immunogenetics. Many of the vaccination
studies reviewed above included only patients with certain
HLA-types known to bind and present the vaccine peptides.
Future studies have to consider how vaccination strategies
should be designed to include all patients and not only
selected subsets. Other immunogenetic factors also need to
be considered then, for example, genetic polymorphisms in
the chemokine system [71] or in T cell regulatory molecules
[110].
6.6. Final Comment. Available studies have demonstrated
that cancer cell vaccines can induce anticancer immune
reactivity. This is possible even for patients with the most
aggressive hematological malignancies that are treated with
very intensive chemotherapy, and it should therefore be
possible also in other malignancies. The future challenge
will now be to design optimal combinations of conventional
disease-reducing therapy (chemotherapy, surgery, and irra-
diation), induction of antigen-speciﬁc immunity through
vaccination and antigen-nonspeciﬁc immunomodulation
(e.g., targeting of Treg and Th17 cells as well as NK cells) to
enhance anticancer reactivity.
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